The relationship between drug clearance and body size: Systematic review and meta-analysis of the literature published from 2000 to 2007

Clinical Pharmacokinetics

Volumn 51, Issue 5, 2012, Pages 319-330

  McLeay, Sarah C ^a   Morrish, Glynn A ^b   Kirkpatrick, Carl M J ^a,c   Green, Bruce ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Model Answers Pty Ltd   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Body weight; Meta analysis; Modelling; Pharmacokinetics; Pharmacology; Population pharmacokinetics

Indexed keywords

ALLOMETRY; BODY DISTRIBUTION; BODY SIZE; BODY SURFACE; BODY WEIGHT; DRUG CLEARANCE; DRUG SAFETY; HUMAN; LEAN BODY WEIGHT; META ANALYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

BODY SURFACE AREA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; OBESITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84859542663     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11598930-000000000-00000     Document Type: Review

References (40)

1. Global database on body mass index (BMI) [online database]. Geneva: World Health Organization, 2009 [online]. Available from URL: http://apps. who.int/bmi/index.jsp?introPage=intro-3.html [Accessed 2012 Mar 5]
2. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82 (5): 505-8 (Pubitemid 47622534)
3. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991; 49: 163-75
4. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58 (2): 119-33 (Pubitemid 39043992)
5. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44 (10): 1051-65 (Pubitemid 41356391)
6. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71
7. Mosteller RD. Simplified calculation of body surface area [letter]. N Engl J Med 1987; 317 (17): 1098
8. Sardinha LB, Silva AM, Minderico CS, et al. Effect of body surface area calculations on body fat estimates in non-obese and obese subjects. Physiol Meas 2006; 27: 1197-209
9. Dooley M, Singh S, Poole S, et al. Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancy [abstract no. 356]. Proc Am Soc Clin Oncol 2002; 21
10. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32 (Pubitemid 351738156)
11. HolfordN.Asize standard for pharmacokinetics.Clin Pharm1996; 30 (5): 329-32
12. Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315-53
13. Rubner M. Uber den Einfluss der Korpergrosse auf Stoff-und Kraftwechsel. Zeitscrift fü r Biologie (Munich) 1883; 19: 535-62
14. Miller AT, Blyth CS. Lean body mass as a metabolic reference standard. J Appl Physiol 1953; 5 (7): 311-6
15. White CR, Seymour RS. Mammalian basal metabolic rate is proportional to body mass 2/3. Proc Natl Acad Sci USA 2003; 100: 4046-9 (Pubitemid 36418154)
16. Mahmood I. Prediction of drug clearance in children: Impact of allometric exponents, body weight, and age. Ther Drug Monit 2007; 29 (3): 271-8 (Pubitemid 47262255)
17. Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009; 24 (1): 57-81
18. Tang H, Hussain M, Leal E, et al. Controversy in the allometric application of fixed-versus varying-exponent models: a statistical and mathematical perspective. J Pharm Sci 2011; 100 (2): 402-10
19. Centres for Disease Control and Prevention, Department of Health and Human Services. Prevalence of overweight, obesity and extreme obesity among adults: United States, trends 1960-62 through 2005-2006. 2009: statistics on overweight and obesity in the US [online]. Available from URL: http://www.cdc.gov/nchs/data/hestat/overweight/overweight-adult.htm [Accessed 2012 Mar 5]
20. Han PY, Kirkpatrick CM, Green B. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn 2009; 36: 147-63
21. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004; 31 (2): 109-34 (Pubitemid 38932393)
22. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46 (3): 221-34 (Pubitemid 46425648)
23. Wang DD, Zhang S, Zhao H, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49 (9): 1012-24
24. Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007; 64 (5): 603-12 (Pubitemid 47568828)
25. Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-5
26. Bulitta JB, Duffull SB, Kinzig-Schippers M, et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51 (7): 2497-507 (Pubitemid 47047329)
27. JorgaK, Fotteler B, Banken L, et al. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 2000; 49: 39-48 (Pubitemid 30050485)
28. Acosta E, Brundage R, King J, et al., for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007; 81 (6): 867-72 (Pubitemid 46788295)
29. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 2007; 63 (1): 41-52 (Pubitemid 44902876)
30. Al Za'abi M, Donovan T, Tudehope D, et al. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. Ther Drug Monit 2007; 29: 807-14 (Pubitemid 350190859)
31. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs 2003; 14 (10): 817-24 (Pubitemid 38339786)
32. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol 2001; 51 (6): 567-76 (Pubitemid 32862745)
33. Fukuda T, Yukawa E, Kondo G, et al. Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. J Clin Pharm Ther 2005; 30: 591-6 (Pubitemid 43960986)
34. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time: EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-86 (Pubitemid 40379262)
35. Lanao J, Calvo M, Mesa J, et al. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 2004; 54: 193-8 (Pubitemid 39028989)
36. Van Obbergh LJ, Roelants FA, Veyckemans F, et al. In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. Can J Anesth 2003; 50 (6): 593-8 (Pubitemid 37038477)
37. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther 2006; 31: 275-82 (Pubitemid 43879758)
38. James W. Research on obesity. London: Her Majesty's Stationary Office, 1976
39. Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72 (6): 743-4 (Pubitemid 36021015)
40. Bouillon T, Shafer SL. Does size matter? Anesthesiology 1998; 89 (3): 557-60 (Pubitemid 28423950)